Biogen (NASDAQ:BIIB) Price Target Raised to $193.00 at Truist Financial

Biogen (NASDAQ:BIIB) had its price target lifted by Truist Financial from $190.00 to $193.00 in a report published on Monday, MarketBeat Ratings reports. Truist Financial currently has a hold rating on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on BIIB. Wedbush raised their target price on Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a report on Monday. Citigroup upped their price objective on Biogen from $180.00 to $185.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 27th. UBS Group assumed coverage on Biogen in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 price objective on the stock. The Goldman Sachs Group reiterated a “buy” rating and issued a $225.00 target price on shares of Biogen in a research report on Thursday, January 8th. Finally, HSBC reissued a “reduce” rating and issued a $143.00 target price (down previously from $144.00) on shares of Biogen in a report on Wednesday, December 10th. Thirteen analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $206.21.

Biogen Trading Down 3.7%

Shares of Biogen stock opened at $193.81 on Monday. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. Biogen has a 12-month low of $110.04 and a 12-month high of $202.41. The company has a market capitalization of $28.43 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.70 and a beta of 0.16. The firm’s 50-day moving average price is $177.26 and its two-hundred day moving average price is $157.48.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, analysts forecast that Biogen will post 15.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 748 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the sale, the insider directly owned 6,271 shares in the company, valued at $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently made changes to their positions in BIIB. Norges Bank acquired a new position in shares of Biogen in the 2nd quarter worth approximately $284,358,000. Orion Porfolio Solutions LLC raised its stake in Biogen by 6,828.4% during the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after buying an additional 509,809 shares during the last quarter. Caisse de depot et placement du Quebec raised its stake in Biogen by 718.2% during the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock worth $79,741,000 after buying an additional 499,676 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Biogen by 30.7% in the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after buying an additional 418,776 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in Biogen by 190.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock valued at $78,415,000 after acquiring an additional 409,591 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.